Our website uses cookies to improve your experience. To make optimal use of this website please agree to our cookie policy.

I agree I do not agree.

Implementation of personalized medicine and pharmaco(epi)genetic biomarkers for improvement of lung cancer treatment


Despite advances in pharmacology, not all lung cancer patients respond favourably to costly therapies. Genetic polymorphisms and epigenetic regulation of transporters, drug-metabolizing enzymes, DNA repair and proteins of cell cycle and apoptosis contribute in interindividual variation in therapy response in Cuban lung cancer patients. In this project, pharmaco(epi)genetic biomarkers will be developed for personalized medicinal health applications, allowing stratification of Cuban lung cancer patients that are more likely to benefit from a given cancer therapy or to prevent adverse reactions of unresponsive patients.

Intervention type

TEAM projects


13/03/2016 - 30/04/2021

This project is being implemented in:
Flemish promoter Wim Vanden Berghe
Local promoter Idania Rodeiro Guerra
Local partner institution Universiteit Antwerpen
visit www.uantwerpen.be
Local partner institution Centre of Marine Bioproducts
Other local partners Centro de Investigación y Desarrollo de Medicamentos
National Institute of Radiology and Oncology
Budget € 299.236